Knight, T. E., Ahn, K. W., Hebert, K. M., Atshan, R., Wall, D. A., Chiengthong, K., … Yanik, G. A. (2023). No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma. Bone Marrow Transplant, 58(12), 1390–1393. https://doi.org/10.1038/s41409-023-02092-3

Knight, Tristan E., Kwang Woo Ahn, Kyle M. Hebert, Rasha Atshan, Donna A. Wall, Kanhatai Chiengthong, Troy C. Lund, et al. “No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma.” Bone Marrow Transplant 58, no. 12 (December 2023): 1390–93. https://doi.org/10.1038/s41409-023-02092-3.

Knight TE, Ahn KW, Hebert KM, Atshan R, Wall DA, Chiengthong K, et al. No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma. Bone Marrow Transplant. 2023 Dec;58(12):1390–3.

Knight, Tristan E., et al. “No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma.” Bone Marrow Transplant, vol. 58, no. 12, Dec. 2023, pp. 1390–93. Pubmed, doi:10.1038/s41409-023-02092-3.

Knight TE, Ahn KW, Hebert KM, Atshan R, Wall DA, Chiengthong K, Lund TC, Prestidge T, Rangarajan HG, Dvorak CC, Auletta JJ, Kent M, Hashem H, Talano J-A, Rotz SJ, Fraint E, Myers KC, Leung W, Sharma A, Bhatt NS, Driscoll TA, Yu LC, Schultz KR, Qayed M, Broglie L, Eapen M, Yanik GA. No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma. Bone Marrow Transplant. 2023 Dec;58(12):1390–1393.